LDS/Medical Tests/Avantect Ovarian Cancer Test

Avantect Ovarian Cancer Test

Ovarian cancer remains one of the most challenging gynecologic malignancies due to its tendency to present with few or nonspecific symptoms in the early stages, leading to diagnosis at advanced disease with poor survival rates. The three major types of ovarian cancer include epithelial tumors (most common), germ cell tumors, and stromal tumors.

The Avantect Ovarian Cancer Test is a liquid biopsy assay that analyzes cell-free DNA (cfDNA) in blood using next-generation sequencing (NGS) with 5-hydroxymethylcytosine (5hmC) enrichment. The assay integrates genomic and epigenomic signals to provide a qualitative result reported as either “Abnormal signal detected” or “Abnormal signal not detected.”

The test has been validated in more than 300 patients, showing a sensitivity of about 78% and a specificity of up to 94%. This performance is better than traditional markers such as CA-125. The Avantect test may be especially helpful for women with a family history of ovarian cancer or genetic risk factors (such as BRCA1/2 mutations) as part of ongoing risk assessment and monitoring. Early detection of abnormal signals may enable timely imaging, biopsy, and clinical intervention, with the potential to improve patient outcomes in high-risk individuals.

  • Supports early detection of ovarian cancer, especially in women at elevated risk (e.g., BRCA1/2 mutations, strong family history)
  • Provides adjunctive information for risk assessment and triage for imaging or biopsy
  • May facilitate preventive interventions or earlier treatment in high-risk individuals
Detected: Abnormal cfDNA signal associated with ovarian cancer. May also occur in benign ovarian conditions. Clinical correlation, oncologic consultation, and follow-up imaging are recommended. Biopsy is required for confirmation. Not Detected: No abnormal signal identified. False negatives are possible; ovarian cancer cannot be entirely excluded. Continued surveillance based on risk factors is recommended.

Not detected (No abnormal signal)

Next-generation sequencing (NGS) with 5hmC enrichment of cfDNA.

Whole blood, EDTA.

Stability

  • Ambient: 3 days
  • Refrigerated: 7 days
  • Frozen: unstable
ROMA (Risk of Ovarian Malignancy Algorithm), Ovarian biopsy (for definitive diagnosis).
7 to 10 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login